| Slide Lecture Programs |
| 2004 Core Curriculum |
Impact of vascular biology on cardiovascular disease, risk prevention, and treatment
Section I: Atrial fibrillation, anticoagulation, and stroke prevention |
April 16, 2004
|
| E: |
Emerging new options
Profile of direct thrombin inhibition" width="220" height="147" border="0">
The ideal oral anticoagulant
|
|
 |
|
 |
|
 |
32 |
 |
| |

Rationale for direct thrombin inhibition: A new anticoagulant strategy
|
|
 |
|
 |
|
 |
33 |
 |
| |

Prothrombotic effects of thrombin
|
|
 |
|
 |
|
 |
34 |
 |
| |

Coagulation cascade: Central role of thrombin
|
|
 |
|
 |
|
 |
35 |
 |
| |

Thrombin binding sites
|
|
 |
|
 |
|
 |
36 |
 |
| |

Direct thrombin inhibitor specificity for the active site
|
|
 |
|
 |
|
 |
37 |
 |
| |

Heparins and direct thrombin inhibitors: Mechanisms of action
|
|
 |
|
 |
|
 |
38 |
 |
| |

Direct thrombin inhibitors block both circulating and clot-bound thrombin
|
|
 |
|
 |
|
 |
39 |
 |
| |

Characteristics of direct thrombin inhibitors
|
|
 |
|
 |
|
 |
40 |
 |
| |

Direct thrombin inhibitors
|
|
 |
|
 |
|
 |
41 |
 |
| |

Ximelagatran pharmacokinetics
|
|
 |
|
 |
|
 |
42 |
 |
| |

Benefits of ximelagatran
|
|
 |
|
 |
|
 |
43 |
 |
| |

SPORTIF III and V: Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation
|
|
 |
|
 |
|
 |
44 |
 |
| |

SPORTIF III and V: Objective and design
|
|
 |
|
 |
|
 |
45 |
 |
| |

SPORTIF III and V: Non-inferiority testing
|
|
 |
|
 |
|
 |
46 |
 |
| |

SPORTIF III and V: Inclusion criteria
|
|
 |
|
 |
|
 |
47 |
 |
| |

SPORTIF III: Quality of warfarin control
|
|
 |
|
 |
|
 |
48 |
 |
| |

SPORTIF III: Primary outcome (stroke and systemic embolism) Intention-to-treat analysis
|
|
 |
|
 |
|
 |
49 |
 |
| |

SPORTIF III: Primary outcome (stroke and systemic embolism) On-treatment analysis
|
|
 |
|
 |
|
 |
50 |
 |
| |

SPORTIF III: Event rate comparisons for secondary composite outcomes
|
|
 |
|
 |
|
 |
51 |
 |
| |

SPORTIF III: Incidence of hemorrhage
|
|
 |
|
 |
|
 |
52 |
 |
| |

SPORTIF III: Incidence of liver enzyme elevation
|
|
 |
|
 |
|
 |
53 |
 |
| |

SPORTIF III: Net clinical benefit
|
|
 |
|
 |
|
 |
54 |
 |
| |

SPORTIF V: Quality of warfarin control
|
|
 |
|
 |
|
 |
55 |
 |
| |

SPORTIF V: Primary outcome (stroke and systemic embolism) Intention-to-treat analysis
|
|
 |
|
 |
|
 |
56 |
 |
| |

SPORTIF V: Primary and sensitivity analyses
|
|
 |
|
 |
|
 |
57 |
 |
| |

SPORTIF V: Incidence of hemorrhage
|
|
 |
|
 |
|
 |
58 |
 |
| |

SPORTIF V: Incidence of liver enzyme elevation
|
|
 |
|
 |
|
 |
59 |
 |
| |

SPORTIF III and V pooled results: Primary outcome
|
|
 |
|
 |
|
 |
60 |
 |
| |

SPORTIF III and V pooled results: Incidence of major bleeding
|
|
 |
|
 |
|
 |
61 |
 |
| |

SPORTIF III and V pooled results: Net clinical benefit
|
|
 |
|
 |
|
 |
62 |
 |
| |

SPORTIF III and V: Conclusions
|
|
 |
|
 |
|
 |
63 |
 |
| |

THRIVE III: Extended secondary prevention of VTE with ximelagatran
|
|
 |
|
 |
|
 |
64 |
 |
| |

THRIVE III: Incidence of hemorrhage
|
|
 |
|
 |
|
 |
65 |
 |
| |

THRIVE III: Time course of liver enzyme elevation
|
|
 |
|
 |
|
 |
66 |
 |
| |

THRIVE III: Conclusions
|
|
 |
|
 |
|